| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
The primary targets of N6-Methyladenosine 5'-monophosphate disodium salt are glycogen phosphorylase b (PYGB) and adenylate kinase II. The compound acts as an activator of glycogen phosphorylase b with a Ka of 22 uM, enhancing glycogen breakdown by promoting enzyme activation and contributing to the regulation of energy metabolism. Additionally, N6-Methyladenosine 5'-monophosphate functions as a noncompetitive inhibitor of rat adenylate kinase II with a Ki of 4.2 mM. Through these interactions, the compound influences adenine nucleotide homeostasis and cellular energy balance. The compound's modified nucleotide structure allows it to interact with enzymes involved in purine metabolism and energy regulation.
|
|---|---|
| ln Vitro |
N6-Methyladenosine 5'-monophosphate disodium salt demonstrates significant in vitro activity as an activator of glycogen phosphorylase b, with a Ka of 22 uM. This activation promotes the breakdown of glycogen, contributing to the regulation of energy metabolism. The compound also acts as a noncompetitive inhibitor of rat adenylate kinase II with a Ki of 4.2 mM, influencing adenine nucleotide homeostasis. In biochemical assays, the compound has been used for immunoprecipitation of N6-methyladenosine, demonstrating its utility in studying RNA modifications. The compound's dual activity-activation of glycogen phosphorylase and inhibition of adenylate kinase-makes it a valuable tool for investigating energy metabolism and purine nucleotide signaling pathways.
|
| ln Vivo |
In vivo activity data for N6-Methyladenosine 5'-monophosphate disodium salt are limited. Based on its in vitro mechanism as an activator of glycogen phosphorylase b (Ka = 22 uM) and a noncompetitive inhibitor of adenylate kinase II (Ki = 4.2 mM), the compound is anticipated to influence glycogen metabolism and energy homeostasis in living systems. As a modified nucleotide, it may participate in cellular signaling pathways related to energy regulation. However, comprehensive pharmacokinetic and pharmacodynamic studies in animal models have not been extensively reported. The compound is primarily used as a research tool for studying glycogen metabolism, purine nucleotide signaling, and RNA modification biology rather than as a therapeutic candidate.
|
| Enzyme Assay |
The in vitro enzyme/receptor binding assay for N6-Methyladenosine 5'-monophosphate disodium salt typically involves measuring its activating effect on glycogen phosphorylase b or its inhibitory effect on adenylate kinase II. For glycogen phosphorylase b activation, the assay system includes purified enzyme, glycogen substrate, and glucose-1-phosphate, with reaction progress monitored by measuring inorganic phosphate release or by coupled enzyme assays. The compound is added at varying concentrations to determine Ka values. For adenylate kinase II inhibition, the assay measures the conversion of ADP to ATP and AMP, with activity detected by coupled enzyme systems using pyruvate kinase and lactate dehydrogenase. Assay buffer typically contains Tris-HCl, magnesium chloride, and potassium chloride at physiological pH. Reactions are incubated at 30-37degC and terminated by addition of stop solution.
|
| Cell Assay |
The in vitro cell-based assay for N6-Methyladenosine 5'-monophosphate disodium salt involves culturing relevant cell lines and treating them with varying concentrations of the compound to assess its effects on glycogen metabolism and cellular energy balance. Cells such as hepatocytes or muscle cells are typically seeded in multi-well plates and incubated with the compound (1-500 uM) for 1-24 hours. Following treatment, glycogen content can be measured using enzyme-linked methods or anthrone reagent. Cellular ATP and AMP levels can be quantified using luciferase-based assays or HPLC to assess the compound's effects on adenine nucleotide homeostasis. Additionally, the compound's effects on RNA modification can be studied by immunoprecipitation of N6-methyladenosine using specific antibodies. The compound is soluble in PBS at 10 mg/mL.
|
| Animal Protocol |
In vivo animal studies for N6-Methyladenosine 5'-monophosphate disodium salt have not been extensively documented in the literature. Based on the compound's mechanism as an activator of glycogen phosphorylase b and an inhibitor of adenylate kinase II, potential animal studies would typically involve administration of the compound via intraperitoneal or intravenous routes in rodent models to assess its effects on glycogen metabolism and energy homeostasis. Dosing would be determined based on preliminary pharmacokinetic data and solubility profiles. Common endpoints in such studies would include evaluation of glycogen levels in liver and muscle tissues, assessment of adenine nucleotide ratios, and monitoring of general toxicity parameters. However, comprehensive in vivo efficacy and toxicity studies have not been widely reported for this compound.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of N6-Methyladenosine 5'-monophosphate disodium salt have not been fully characterized in the literature. The compound has a molecular weight of 407.23 g/mol and a molecular formula of C11H14N₅Na2O₇P. It is a crystalline solid with a purity of ≥95%. The compound is soluble in PBS (pH 7.2) at 10 mg/mL and exhibits UV absorbance maxima at 210 nm and 266 nm. For storage, the compound should be kept at -20degC and shipped at room temperature. The compound's phosphate group and sodium salt form contribute to its hydrophilic nature, which may limit passive membrane permeability and oral bioavailability. The compound is stable under recommended storage conditions.
|
| Toxicity/Toxicokinetics |
Toxicity data for N6-Methyladenosine 5'-monophosphate disodium salt are limited, as the compound is a research-use nucleotide and has not undergone extensive toxicological characterization. Standard safety precautions should be followed when handling this compound, including the use of appropriate personal protective equipment such as gloves and lab coats to prevent skin contact and inhalation of dust. The compound should be handled in a well-ventilated area. In case of accidental exposure, rinse affected areas with plenty of water and seek medical attention if irritation persists. Proper waste disposal procedures should be observed in accordance with local regulations. As with all research chemicals, exposure should be minimized and the compound should be stored securely at -20degC away from incompatible materials.
|
| Additional Infomation |
N6-Methyladenosine 5'-monophosphate disodium salt (CAS#: 81921-35-9) is a modified nucleotide with the molecular formula C11H14N₅Na2O₇P and a molecular weight of 407.23. Also known as N6-methyl-AMP, this compound functions as an activator of glycogen phosphorylase b (Ka = 22 uM) and a noncompetitive inhibitor of rat adenylate kinase II (Ki = 4.2 mM). It enhances glycogen breakdown by promoting enzyme activation and contributes to the regulation of energy metabolism. The compound has been used for immunoprecipitation of N6-methyladenosine, making it a valuable tool for studying RNA modifications. It is a crystalline solid with a purity of ≥95%, soluble in PBS (pH 7.2) at 10 mg/mL, and should be stored at -20degC. The compound is intended for research purposes only. No clinical trials or regulatory approvals have been reported.
|
| Molecular Formula |
C11H14N5O7P-2.2[NA+]
|
|---|---|
| Molecular Weight |
405.21156
|
| Exact Mass |
384.069
|
| CAS # |
81921-35-9
|
| PubChem CID |
71299667
|
| Appearance |
White to light brown solid powder
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
26
|
| Complexity |
484
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C=NC2C(=NC=NC1=2)NC.[Na]
|
| InChi Key |
HFOKUKRAZPHTHH-LYYWGVPGSA-L
|
| InChi Code |
InChI=1S/C11H16N5O7P.2Na/c1-12-9-6-10(14-3-13-9)16(4-15-6)11-8(18)7(17)5(23-11)2-22-24(19,20)21;;/h3-5,7-8,11,17-18H,2H2,1H3,(H,12,13,14)(H2,19,20,21);;/q;2*+1/p-2/t5-,7-,8-,11-;;/m1../s1
|
| Chemical Name |
disodium;[(2R,3S,4R,5R)-3,4-dihydroxy-5-[6-(methylamino)purin-9-yl]oxolan-2-yl]methyl phosphate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~100 mg/mL (~246.79 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4679 mL | 12.3393 mL | 24.6786 mL | |
| 5 mM | 0.4936 mL | 2.4679 mL | 4.9357 mL | |
| 10 mM | 0.2468 mL | 1.2339 mL | 2.4679 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
